ARC1779 ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
64	血栓性血小板減少性紫斑病	2
288	自己免疫性後天性凝固因子欠乏症	4

64. 血栓性血小板減少性紫斑病

臨床試験数 : 86 / 薬物数 : 81 - (DrugBank : 20) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 63

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00726544 (ClinicalTrials.gov)	December 2008	30/7/2008	Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy	A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779Injection in Patien ...	Thrombotic Microangiopathy;Thrombotic Thrombocytopenic Purpura	Drug: ARC 1779 Placebo;Drug: ARC1779 Injection	Archemix Corp.	NULL	Terminated	18 Years	75 Years	Both	100	Phase 2	United States;Austria;Canada;Italy;United Kingdom
2	EUCTR2007-004371-19-AT (EUCTR)	20/11/2007	12/12/2007	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779Injection in P ...	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779Injection in P ...	von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP ...	Product Name: ARC1779Injection Product Code: ARC1779 Other descriptive name: ARC 1779 Trade Name: Octos ...	Archemix Corp.	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	Austria

First Previous1Next Last

288. 自己免疫性後天性凝固因子欠乏症

臨床試験数 : 205 / 薬物数 : 238 - (DrugBank : 31) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 26

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-008532-82-AT (EUCTR)	19/02/2009	21/01/2009	A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779Injection in Pati ...	A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779Injection in Pati ...	von Willebrand Disease type 2B	Product Name: ARC1779 Product Code: ARC1779	Medical University of Vienna, Dept. of Clinical Pharmacology	NULL	Not Recruiting			Female: yes Male: yes			Austria
2	NCT00694785 (ClinicalTrials.gov)	October 2008	6/6/2008	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779Injection in Patients With V ...	A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779Injection in Patients With V ...	Von Willebrand Disease	Drug: ARC1779	Archemix Corp.	NULL	Withdrawn	16 Years	75 Years	Both	2	Phase 2	NULL
3	NCT00632242 (ClinicalTrials.gov)	January 2008	3/3/2008	ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779Injection in P ...	Purpura, Thrombotic Thrombocytopenic;Von Willebrand Disease Type-2b	Drug: ARC1779	Archemix Corp.	NULL	Completed	18 Years	75 Years	Both	28	Phase 2	Austria
4	EUCTR2007-004371-19-AT (EUCTR)	20/11/2007	12/12/2007	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779Injection in P ...	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779Injection in P ...	von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP ...	Product Name: ARC1779Injection Product Code: ARC1779 Other descriptive name: ARC 1779 Trade Name: Octos ...	Archemix Corp.	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	Austria

First Previous1Next Last

先頭へ